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Adjuvant chemotherapy in
stage IB non-small cell lung
are  presented  in  Table  1.  Median  follow-up  time  was  52.1
months.a
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dcarcinoma: A survival analysis
Dear  Editor,
Surgery  is  the  primary  treatment  modality  for  non-small
cell  lung  cancer  (NSCLC),  but  only  approximately  20%  of
tumors  are  suitable  for  potentially  curative  resection  and
even  after  surgery,  with  a  high  percentage  of  recurrence
probability.1,2 Therefore,  5-year  survival  rates  after  surgery
are  disappointingly  low2 and  new  strategies  are  needed  to
reduce  mortality  and  recurrence  rate  in  these  patients.
Stage  IB  NSCLC  therapeutic  approach  remains  a  controver-
sial  issue.  Adjuvant  chemotherapy  among  this  particular
group  of  patients  has  never  been  demonstrated  unequivo-
cally  as  improving  survival.1,2
Based  on  recent  evidence,3 the  National  Comprehensive
Cancer  Network  (NCCN)  guidelines1 included  an  indication
for  adjuvant  chemotherapy  for  high-risk  stage  IB  NSCLC
patients.  These  high-risk  factors  include  tumor  >4  cm,  poorly
differentiated  tumor,  vascular  invasion,  visceral  pleura
involvement,  wedge  resection,  and  incomplete  lymph  node
sampling  (Nx).  In  order  to  evaluate  the  impact  of  adju-
vant  chemotherapy  on  stage  IB  NSCLC  patients  undergoing
surgery,  we  reviewed  our  center  experience  with  these
patients.
All  completely  resected  stage  IB  NSCLC  patients  observed
during  the  period  between  January  2006  and  December  2013
were  included.  Only  patients  with  proven  pT2N0  samples
were  consecutively  enrolled.  To  ensure  maximum  homo-
geneity,  patients  who  had  received  induction  chemotherapy
were  excluded,  even  if  their  deﬁnitive  staging  was  pT2N0.
We  then  analyzed  the  effect  of  adjuvant  chemotherapy,
irrespective  of  the  indication,  on  survival  data  of  all  patients
included  and  of  a  high-risk  patients’  subgroup,  as  deﬁned
by  the  NCCN  guidelines.  The  adjuvant  chemotherapy  regi-
men  consisted  of  four  courses  of  a  platinum  derivative  and
vinorelbine.
We  analyzed  27  patients  with  a  mean  age  of  65.3  ±  8.87
years  and  predominantly  male  (n  =  18;  66.7%).  Over  90%  of
patients  had  performance  status  ≤1  at  diagnosis.  There  was
no  perioperative  mortality  (death  within  30  days  of  surgery).
General  and  high-risk  subgroup  population  characteristics
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djuvant  chemotherapy  group  and  4  in  the  non-adjuvant
hemotherapy  group).  Mean  disease-free  time  was  45.3
onths  for  the  adjuvant  chemotherapy  group  and  33.6
onths  for  the  non-adjuvant  chemotherapy  group  and  there
as  no  statistically  signiﬁcant  difference  between  the  two
roups.  Eight  (29.6%)  deaths  occurred  in  the  study  group
3  in  the  adjuvant  chemotherapy  group  and  5  in  the  non-
djuvant  chemotherapy  group).  Mean  survival  time  was
0.0  months  for  the  adjuvant  chemotherapy  group  and  36.4
onths  for  the  non-adjuvant  chemotherapy  group  and  again
here  was  no  statistically  signiﬁcant  difference  between  the
wo  groups.
As  for  the  high-risk  subgroup,  19  patients  had  at  least
ne  NCCN  high-risk  factor.  Mean  disease-free  time  was  43.3
onths  for  the  adjuvant  group  and  32.8  months  for  the
on-adjuvant  group,  with  no  statistically  signiﬁcant  dif-
erence  between  the  two  groups.  Mean  survival  time  was
8.9  months  for  the  adjuvant  chemotherapy  group  and  34.0
onths  for  the  non-adjuvant  chemotherapy  group.  No  sta-
istically  signiﬁcant  difference  was  found  between  the  two
roups.
Our  study  did  not  ﬁnd  any  clear  beneﬁt  for  the  NCCN’s
igh-risk  patients  in  terms  of  overall  survival  and  disease-
ree  survival,  and  the  same  holds  for  all  NSCLC  stage  IB
atients  who  underwent  surgical  treatment.  Despite  this
vidence,  we  did  ﬁnd  a  non-signiﬁcant  difference  in  terms
f  overall  survival  and  disease  free  survival  between  non-
djuvant  chemotherapy  and  adjuvant  chemotherapy  group,
ith  an  improvement  of  both  in  the  latter  group.  Although
bviously  limited  by  our  sample  size  and  by  the  fact  that
he  non-adjuvant  chemotherapy  group  had  a  higher  ratio  of
neumectomies,  which  is  associated  with  poorer  survival,5
his  might  indicate  that  adjuvant  chemotherapy  can  play  an
mportant  role  in  the  treatment  of  these  patients.
Unfortunately,  adjuvant  chemotherapy  role  in  stage  IB
isease  is  not  established  yet.  As  in  our  study,  subgroup
tage  IB  analyses  of  larger  trials  have  found  a  small  but  non
igniﬁcant  overall  survival  beneﬁt.1,2 Recent  evidence  has
emonstrated  a  signiﬁcant  beneﬁt  of  adjuvant  chemother-
3py  in  stage  IB  patients  with  larger  primary  tumors  (4.0  cm)
nd  the  same  seems  to  hold  for  stage  IB  patients  with  vascu-
ar  invasion.6 In  spite  of  these  results,  at  this  point  in  time
lsevier España, S.L.U. All rights reserved.
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Table  1  General  population  and  high-risk  subgroup  population  characteristics.
General  population
Adjuvant  chemotherapy  (n  =  13) Non-adjuvant  chemotherapy  (n  =  14)
Age  (mean  ±  SD)  62.2  ±  7.80  68.1  ±  9.15
Gender (male/female)  9/4  9/5
PS >  1  (yes/no)  0/13  2/12
Histological  type
Adenocarcinoma  8  11
Squamous  cell  carcinoma 4  3
Large cell  carcinoma 1  0
Heart disease  (yes/no) 2/11  2/12
Smoking  history  (yes/no)  3/10  4/10
Resection  type
Pneumonectomy  1  3
Lobectomy  11  6
Bilobectomy  1  3
Wedge resection  0  2
High-risk  subgroup  population
Adjuvant  chemotherapy  (n  =  11)  Non-adjuvant  chemotherapy  (n  =  8)
Age  (mean  ±  SD)  62.1  ±  7.94  71.9  ±  8.46
Gender (male/female)  7/4  6/2
PS >  1  (yes/no)  0/11  2/6
Histological  type
Adenocarcinoma  7  7
Squamous  cell  carcinoma  3  1
Large cell  carcinoma  1  0
Heart disease  (yes/no)  1/10  2/6
Smoking  history  (yes/no)  8/3  6/2
Resection  type
Pneumonectomy  1  2
Lobectomy  10  3
Bilobectomy  0  1
Wedge resection 0  2
Num of  NCCN  risk  factors
1 5  5
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here  is  no  available  evidence  to  formally  support  routine
se  of  adjuvant  chemotherapy  in  stage  IB.1,2,4
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Non-small cell lung cancer in
young patients -- A
retrospective analysis of 10
years in a tertiary university
hospital
Dear  Editor,
Non-small  cell  lung  cancer  (NSCLC)  in  young  adults  is
uncommon.  Although  there  is  limited  data  about  clinical
presentation  and  outcomes,  it  does  seem  that  this  popu-
lation  has  some  distinct  clinicopathological  characteristics
and  given  the  signiﬁcant  socio-economic  implications  NSCLC
in  young  adults  is  increasingly  important.1--3
The  authors  report  the  incidence,  clinical  characteristics,
treatment  and  prognosis  of  NSCLC  in  young  patients  (≤45
years),  in  a  tertiary  academic  hospital  in  Oporto.  We  ret-
rospectively  evaluated  2430  patients  newly  diagnosed  with
lung  cancer,  from  January  2005  to  December  2014.  Our  study
identiﬁed  78  (3.2%)  young  adults.  For  analysis  purpose,  it
only  included  patients  with  NSCLC  who  were  followed  up  in
our  center.
Fifty-nine  (75.6%)  young  adults  were  included:  37  (62.7%)
were  male  with  a  mean  age  of  40.8  years  (SD  ±  3.8).  40
(67.8%)  patients  of  the  patients  had  a  history  of  smoking.
The  median  time  from  symptom  onset  to  diagnosis  was
1.0  months  (0--12.0).  Adenocarcinoma  was  the  most  com-
mon  histopathological  type,  recorded  in  44  (74.6%)  patients,
followed  by  squamous  cell  carcinoma  in  7  (11.9%).  EGFR
mutations  and  ALK  translocation  were  recorded  in  only  11
(18.7%)  patients,  and  EGFR  activating  mutations  were  found
in  2  (18.2%).  The  clinical  staging  revealed  5  (8.5%)  patients
with  NSCLC  in  stages  I  and  II,  6  (10.2%)  III-A  and  48  (81.4%)
III-B  and  IV.  The  initial  Performance  Status  (PS)  was  0  and
1  in  41  (69.5%)  patients,  2  in  6  (10.2%),  and  3  and  4  in  8
(13.6%).
Surgical  resection  was  performed  in  9  (15.3%)  patients,
of  whom  7  received  chemotherapy  and  2  received  chemo-
radiotherapy.  In  patients  undergoing  to  surgery,  lobectomy
and  mediastinal  lymph  node  dissection  was  performed  in  7
and  pneumonectomy  in  2.  Chemotherapy  alone  was  given  to
(n  =  41).  After  progression,  half  of  the  patients  (n  =  29)
were  treated  with  second-line  chemotherapy  and  18.6%
(n  =  11)  patients  to  third-line.  A  minority  (11.9%)  of  patients
received  best  supportive  care  (BSC)  as  initial  treatment.
Regarding  response  to  ﬁrst-line  treatment,  5  (8.5%)  patients
obtained  a  complete  response,  8  (13.6%)  obtained  a  par-
tial  response,  3  (5.1%)  stabilized,  and  the  majority  (72.9%)
progressed.  The  median  progression-free  survival  was  4.0
months  (0--39.0).
During  the  follow-up  period  only  12  (20.3%)  patients  were
still  alive.  In  Kaplan--Meier  analyses,  the  median  survival
rate  was  about  1.5  months  in  BSC  group  and  9.0  months
in  those  submitted  to  other  non-surgical  treatments.  Six
(66.7%)  operated  patients  are  still  alive  (Fig.  1).
Lung  cancer  is  considered  a  disease  of  the  elderly.
The  incidence  among  young  adults  has  been  found  to  be
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Best supportive care32  (54.2%)  patients  and  combination  chemo-radiotherapy  to
11  (18.6%).  Platinum-based  doublet  regimens  were  used  as
ﬁrst-line  chemotherapy  in  more  than  two  thirds  of  patients
F
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pig.  1  Kaplan--Meier  survival  curves  according  to  treatment
erformed  (surgery,  other  non-surgical  treatments  and  best  sup-
ortive  care).
